prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - Subtype Normal, Procedure Date: Procedure Physician: Attending Physician/Copies To: PATIENT HISTORY: DATE OF LMP: DATE OF LAST DELIVERY: PRE-OP DIAGNOSIS: R BREAST CANCER. POST-OP DIAGNOSIS: SAME. OPERATIVE PROCEDURE: RIGHT MODIFIED RADICAL MASTECTOMY. CLINICAL HISTORY. MATERIAL SUBMITTED: RIGHT (MOD) RADICAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDURE. INTRAOPERATIVE CONSULTATION: FROZEN SECTION: Right breast measuring 18.0 by 17.0 by 5.2 cm with 16.0 by 6.3 cm skin and nipple and. partial axillary contents. A tan-white irregular mass measuring 1.8 by 1.0 by 1.2 Cm is identified 1.3 cm. from the deep resection margin. Mass lies in the center of the mass. FS Diagnosis: Infiltrating duct. carcinoma. ER/PRS taken. (1. Delow. FINAL DIAGNOSIS: RIGHT BREAST MASS AND AXILLARY CONTENTS: - MULTIFOCAL INVASIVE DUCTAL CARCINOMA, 1.8 BY 1.2 BY 1.0 CM., POOR NUCLEAR GRADE. - EXTENSIVE DUCTAL CARCINOMA IN-SITU, COMEDO TYPE. - VASCULAR PERMEATION SEEN. - SKIN, NIPPLE AND DEEP MARGINS FREE OF TUMOR. - FIVE (5) LYMPH NODES FREE OF TUMOR. - HEMORRHAGE AND HEMOSIDERIN LADEN MACROPHAGES CONSISTENT WITH BIOPSY SITES. - FIBROCYSTIC CHANGES. NOTE: Within the invasive tumor, the ductal carcinoma ;in-situ component is about 30%. S U P P L x M E N T R E P o R T. (HER2/NEU). My signature below is attestation that I have reviewed all slides and agree with the findings as noted. below. AS PER THE REQUEST OF. OF THE. c-erb82 (HER-2/NEU). DMMUNOSTAINING IS CARRIED OUT ON PREVIOUS MAGKE SURGICAS. BBOCK "A4" (BREAST CANCER) USING A 1:300. DILUTION of DAKO'S POLYCLONAL ANTIBODY A485 (DIRECTED AGAINST THE INTRACELLULAR DOMAIN OF c-erbB2) WITHOUT. ANTIGEN RETRIEVAL. DISTINCT COMPLETE MEMBRANE STAINING IS IDENTIFIED IN 90% OF TUMOR CELLS THEREFORE, c-. erbB2 (HER-2/NEU) IS INTERPRETED AS POSITIVE (SCORE 3+). SIGNED COPY ON FILE. s. (ER/PR). My signature below is attestation that I have reviewed all slides and agree with the findings as noted. below. IMMUNOPEROXIDASE IDENTIFICATION OF ESTROGEN AND PROGESTERONE RECEPTORS IS CARRIED OUT ON SLIDE. "A4". DISTINCT INTRANUCLEAR STAINING IS IDENTIFIED TOCALLY FOR PROGESTERONIS RECEPTOR (20%) BUT NOT FOR. ESTROGEN RECEPTOR. THEREFORE, PROGESTERONE RECEPTOR IS INTERPRITED AS BOR DERLINE AND ESTROGEN RECEPTOR AS. NEGATIVE.

expanded version (tokens=1116) : 
 Histological Classification:
- Multifocal Invasive Ductal Carcinoma
- Extensive Ductal Carcinoma In-Situ, Comedo Type

Subtype: Not specified

Description of Necrosis: Not mentioned in the report

Tumor Infiltrating Lymphocytes: Not mentioned in the report

Histological Grade: Poor Nuclear Grade

Nuclear Grade: Not specified for invasive ductal carcinoma

Lymphovascular Invasion: Vascular Permeation Seen

Calcification: Not mentioned in the report

Receptor Status: 
- ER/PR: Estrogen receptor negative and Progesterone receptor borderline
- c-erbB2 (HER2/NEU): Positive, score 3+

IHC and Ancillary Testing Results: 
- ER/PR testing was carried out using immunoperoxidase identification, which identified distinct intranuclear staining for progesterone receptor but not for estrogen receptor. 
- c-erbB2 (HER2/NEU) testing was carried out using immunostaining with polyclonal antibody A485 and identified distinct complete membrane staining in 90% of tumor cells, interpreting it as positive (score 3+). 

Other ancillary testing results mentioned in the report: None.

prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=1261) : 
 Report shows multifocal invasive ductal carcinoma with extensive ductal carcinoma in-situ, comedo type. Poor nuclear grade with vascular permeation seen. ER/PR receptor status is estrogen receptor negative and progesterone receptor borderline. c-erbB2 (HER2/NEU) receptor is positive with a score of 3+. No mention of tumor infiltrating lymphocytes, necrosis, lymphovascular invasion or calcification. No other ancillary testing results were observed.

